Ginkgo Bioworks and Google Cloud Partner to Build Next Generation AI Platform for Biological Engineering and Biosecurity (August 29, 2023) | By Ginkgo Bioworks. Ginkgo and Google Cloud enter strategic five-year cloud and AI partnership Ginkgo to pioneer new large language models for biological engineering applications, powered by Google Cloud’s Vertex AI platform Ginkgo intends
Continue ReadingGinkgo Bioworks Awarded DARPA Contract to Reimagine the Manufacturing of Complex Therapeutic Proteins (July 19, 2023) | By BioSpace. ARLINGTON, Va. and BOSTON, July 19, 2023 /PRNewswire/ — Approved for Public Release, Distribution Unlimited — Defense Advanced Research Projects Agency (DARPA) announced that Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell
Continue ReadingDTx Pharma announces acquisition by Novartis (July 17, 2023) | By Christina Trout – DTx Pharma. DTx Pharma’s Fatty Acid Ligand Conjugated Oligonucleotide (FALCON™) platform facilitates extra-hepatic delivery of siRNA therapeutics Acquisition includes DTx-1252 with the potential to deliver a transformative medicine to Charcot-Marie-Tooth Disease Type 1A (CMT1A) patients Acquisition also includes additional early-stage programs in
Continue ReadingTakeda, F-star Sign Potential $1B Immuno-Oncology Agreement (July 7, 2023) | By Tristan Manalac. Takeda has entered into a strategic discovery collaboration and licensing agreement with British biotech F-star Therapeutics to develop next-generation and multi-specific antibodies for undisclosed cancer indications, the companies announced Wednesday. The partners did not reveal how much Takeda paid upfront
Continue ReadingLilly Aims to Boost Immuno Business with $2.4B DICE Buy (June 20, 2023) | By Tristan Manalac. To deepen its autoimmune disease portfolio, Eli Lilly is acquiring California-based biopharma DICE Therapeutics for more than $2 billion, the pharmaceutical giant announced Tuesday. Under the terms of the deal, Lilly will buy all of DICE’s outstanding shares
Continue ReadingBoehringer and Ginkgo Ink Potential $400M+ Metagenomics Deal for “Undruggable” Targets (May 8, 2023) | By Inside Precision Medicine. Ginkgo Bioworks today announced a new partnership with Boehringer Ingelheim to use Ginkgo’s metagenomic sequence database to find candidates to address undruggable targets. The two companies will leverage Ginkgo’s natural product discovery capabilities to “accelerate the
Continue ReadingBiomica Announces Closing of $20 Million Financing Round led by Shanghai Healthcare Capital (April 27, 2023) | By Biomica Ltd. REHOVOT, Israel, April 27, 2023 /PRNewswire/ — Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced that it has closed a financing
Continue ReadingVedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies Financing will enable pivotal Phase 3 study of VE303 for recurrent C. difficile infection, to begin by 3Q 2023 Funds will also support Phase 2 study of VE202 for ulcerative colitis, to begin in 2Q 2023 Syndicate led by new investors
Continue ReadingDSM agrees terms to acquire postbiotics pioneer Adare Biome (April 19, 2023) | By Microbiome Times. Royal DSM, a global science-based leader in health, nutrition, and bioscience, announces that it has entered into exclusive negotiations with Adare Pharma Solutions in order to acquire Adare Biome, a pioneer in the development and manufacturing of postbiotics, for
Continue ReadingGinkgo, hunting for biotech platforms that ‘collect dust,’ scoops up AAV gene therapy capsid specialist (April 5, 2023) | By Annalee Armstrong. Ginkgo Bioworks doesn’t want the biotech industry’s therapies. But it does want the platforms that create them, which is why the cell programming company is buying up StrideBio for its gene therapy intellectual
Continue Reading